source
- Longeveron’s pediatric heart stem-cell trial misses primary endpoint, prompting cost cutsLongeveron reported that its phase 2b Elpis II trial of the stem-cell product laromestrocel in infants with hypoplastic left heart syndrome failed to meet its primary efficacy endpoint. The study…
- Senate schedules hearing for FDA nominee as Novo teams with Anthropic on AI drug developmentThe Senate has announced a hearing to consider the nominee for the next FDA commissioner, signaling a forthcoming review of the agency's leadership. In parallel, biotech firm Novo has entered a pa…